G-Pep RD Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, leading to sustained acid suppression and promoting mucosal healing. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance by reducing dosing frequency. G-Pep RD Capsule SR is indicated for patients requiring both acid suppression and prokinetic therapy, particularly in cases of GERD with delayed gastric emptying. It should be used under medical supervision, with caution advised in patients with known hypersensitivity to either component, hepatic impairment, or underlying cardiac conditions. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. This combination therapy offers a synergistic approach to symptom relief and mucosal protection in acid-related gastrointestinal disorders.